Fact based stock research
Sun Pharmaceuticals (NSEI:SUNPHARMA)


Sun Pharmaceuticals stock research in summary

sunpharma.com


Sun Pharmaceuticals shares have a BUY rating. While they are safely financed, they are bad value, and show below average growth. We recommend buying and holding Sun Pharmaceuticals shares.


Latest Obermatt Ranks


Country India
Industry Pharmaceuticals
Index BSE Sensex, CNX Nifty 50
Size class Large

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: Sun Pharmaceuticals

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
44
73
64
44
STOCK GROWTH RANKS
32
40
5
33
STOCK SAFETY RANKS
68
80
29
91
COMBINED STOCK RANKS
35
80
60
100

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Sun Pharmaceuticals in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Sun Pharmaceuticals; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
94
16
5
17
PROFIT GROWTH
10
33
33
50
STOCK RETURNS
20
28
48
33
CONSOLIDATED RANK: GROWTH
32
40
5
33

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Sun Pharmaceuticals.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
51
55
60
58
REFINANCING
39
46
40
44
LIQUIDITY
100
100
100
100
CONSOLIDATED RANK: SAFETY
68
80
29
91

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Sun Pharmaceuticals and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Sun Pharmaceuticals from June 8, 2018.